TrakCel company overview
About
Expert Vetted Data
Public disclosures rarely capture a company's internal dynamics or the true state of its technology. Gain first-hand insight by speaking with former TrakCel executives.
Ownership & Key Financials
Revenue
Investors
Revenue / FTE
Ownership
FTEs
Products & Services
SaaS Software
Description: Modular cellular orchestration platform built on Salesforce for managing end-to-end cell and gene therapy supply chains from patient enro•••••• ••••••• ••••••••• ••••••••.••••: ••••••• •• •••••••, ••••••• •••-••-•••-••, ••••••• ••••, ••••••• ••••••• ••••: •••• •• •••••••••••••• ••• ••••••••••••• ••••••••• ••• ••••••• ••••••••••, ••••••••••, ••••••••••••• ••••••••••••, ••••••••• ••••••••••, ••• •••••••••• •••••••••• •••••••• •••••• •••••••• •••••• ••• •••••••••• ••••••• ••••••••••.••• ••••••••: ••• ••••••••••••, ••••••••••••• ••••••••• ••••••••••, •••••••• ••••••• ••••••••••, ••• ••••••••••, ••••• ••••••••••, •••••••••••-•••••••••• •••••••••, ••••••••• ••••••••, •••• •••••••• ••••••••••
Professional Services
Description: Comprehensive consulting and implementation services for cell and gene therapy supply chain design, deployment, and operational support.N•••: ••••••• ••••••••, •••••••••••••• ••••••••, ••••••• & •••••••••• ••••••••••, •••••••• ••••••••, ••••••• ••••••••, ••••••• ••••••••••••• ••••: •••• •• ••••••• •••••••••• •• ••••••••• ••••••••••••• •••••••••, •••••• •••••••••• ••••••••••, •••••• •••••• ••••• •••••••••, ••• ••••••• ••••••• ••••••••••• ••••••• ••• •••••••• •••••• ••• •••••••••• ••••••••••.••• ••••••••: •••••••• •••••• •••••••••• (•••), ••• •••••••••• •••••••, ••••/••••• ••••••••••, ••••• •••••••, •••••• ••••• •••• ••••••••••, •••• ••••••••••, ••/• •••••••• •••••••
Pricing & Go-to-market
Typical Contract Length
••••••
Pricing model
Multi-component pricing structure including Salesforce user license fees, Mulesoft licensing, and time-and-materials professional services for impleme•••••••. •••-••-•••-•• ••••• •••• •• ••••••• •••• ••••• •••••••• ••• •••• ••• •••••••• ••••••••.
Average Sales Value
$•••,•••
Average Sales Cycle
•• •• •• ••••••
Growth Review
| Company Name | Revenue | FTE | Proprietary Insights | HQ | Ownership Type |
|---|---|---|---|---|---|
| | $1•m '•• | •• '•• | - | UK | A••••••• |
| | - | - | ••••••• ••• •••••• •••• •••••••••••• ••••••••• ••• •••• ••• •••• ••••••• ••••••••• •••••••• •••••• •... | - | V•••••••• |
| | - | - | - | - | P••••• |
| | - | - | •••••••• •• • ••••••, ••••••-••••••• •••••••••• •• •••••••, •••••••• ••••••• ••••••••••-•••••• •••••... | - | F•••••••••••• |
| | - | - | - | - | P••••• |
Experts highlight TrakCel's technical capabilities and platform strength, while noting integration execution as a potential constraint.
What does Origin provide on TrakCel?
Origin provides a structured company snapshot of TrakCel, combining expert-led insights with analysis across business model, customers, competitors, and market dynamics. The profile is designed to support research, competitive analysis, and commercial due diligence workflows.
How is Origin's analysis of TrakCel different from traditional company databases?
Traditional company databases often focus on surface-level metadata such as ownership, funding, and company descriptions. Origin complements these sources with qualitative insights informed by expert interviews, helping teams understand how TrakCel operates, competes, and creates value in practice.
Is Origin suitable for researching private companies like TrakCel?
Yes. Origin is built to support research on private companies, where public information can be limited or inconsistent. It focuses on insight depth and operational context, which can be useful when evaluating companies like TrakCel for investment, partnership, or competitive analysis.
Where does Origin's information on TrakCel come from?
Origin insights are derived from expert interviews conducted by Dialectica, combined with structured analysis and secondary validation where appropriate. This approach prioritises first-hand operational perspectives alongside supporting evidence, rather than relying solely on aggregated public data.
Can Origin support commercial due diligence on TrakCel?
Origin can support early-stage commercial due diligence by helping teams quickly understand positioning, value drivers, customer dynamics, and potential risks related to TrakCel. It is typically used to shape hypotheses and focus areas before deeper primary research.
How does Origin compare to Crunchbase or PitchBook for analysing TrakCel?
Crunchbase and PitchBook primarily focus on company metadata, ownership, funding history, and transactions. Origin complements those sources by adding qualitative, insight-led analysis focused on business fundamentals, go-to-market execution, customer reality, and competitive positioning for companies like TrakCel.
How is Origin used to analyse post-acquisition risks and priorities for TrakCel?
After an acquisition, Origin can help teams understand where value creation may be driven or constrained, including product overlap, customer retention dynamics, and go-to-market integration priorities. It can also highlight areas where TrakCel may face competitive pressure or internal execution risk during integration.
What does Origin typically reveal about pricing and go-to-market strategy for enterprise software companies like TrakCel?
For enterprise software, Origin often focuses on pricing logic, contract structure, buyer personas, procurement friction, and channel strategy. For companies like TrakCel, this can help teams assess how revenue is created, what drives expansion, and where sales cycles or retention may impact outcomes.
Relevant Companies
1upHealth, Inc.
Cloud-native, FHIR-standard healthcare data management platform for payers, providers, and life sciences organizations to acquire, manage, share, and analyze clinical and claims data for interoperability and analytics
HQ
AIMA
Healthcare revenue cycle management solution for genetic testing companies and clinical providers to manage billing, coding, compliance, accounts receivable, and administrative operations.